Phathom Pharmaceuticals (PHAT) Loss Compression Challenges Bearish Narratives After Q1 2026 Results

Q1 2026 earnings snapshot and recent momentum

Phathom Pharmaceuticals (PHAT) has just reported its Q1 2026 numbers, with the most recent quarterly reference period showing total revenue of US$57.6 million and a basic EPS loss of US$0.29, alongside net income excluding extra items at a loss of US$21.1 million. Over the past year of reported quarters, revenue has moved from US$29.7 million in Q4 2024 through to US$28.5 million, US$39.5 million, US$49.5 million and then US$57.6 million, while basic EPS losses over those same quarters shifted from US$1.05 to US$1.31, US$1.05, US$0.41 and US$0.29. For investors, the headline story is that revenue growth ambitions and earnings forecasts are running against a backdrop of ongoing losses, so the focus now is on how quickly margins can tighten and move the business closer to break even.

See our full analysis for Phathom Pharmaceuticals.

With the latest figures on the table, the next step is to weigh these results against the stories investors have been telling about Phathom, to see which narratives line up with the data and which start to look out of sync.

See what the community is saying about Phathom Pharmaceuticals

Losses shrink from US$94.3m to US$21.1m over six quarters

• Net income excluding extra items has been in loss territory across the past six reported quarters, moving from a loss of US$94.3 million in Q1 2025 and US$85.6 million in Q3 2024 to a loss of US$21.1 million in Q4 2025, alongside a trailing twelve month loss of US$221.2 million as of Q4 2025.
• What stands out for the bullish view is that analysts expect earnings to grow about 51.7% per year and move into profitability within three years. That optimism sits against a recent history where losses on a trailing basis were as large as US$345.8 million, which means:
  • Bulls point to the combination of higher revenue forecasts and margin improvement, but the current loss profile shows the scale of the turnaround implied in that story.
  • The shift from quarterly losses in the US$70 million to US$90 million range down to US$21.1 million helps the bullish case, while the still large trailing twelve month loss reminds you this is not yet a small clean up job.

Phathom’s recent progress on quarterly losses is exactly the kind of trend bullish investors focus on, but the size of the trailing deficit shows why the full bull argument is more detailed than one quarter’s numbers alone, and that is laid out in the 🐂 Phathom Pharmaceuticals Bull Case.

Revenue climbs to US$175.1m on a trailing basis

• On a trailing twelve month view to Q4 2025, total revenue reached US$175.1 million, compared with earlier trailing figures of US$81.9 million and US$55.3 million, while individual quarters stepped through US$16.4 million, US$29.7 million, US$28.5 million, US$39.5 million, US$49.5 million and US$57.6 million.
• Consensus narrative points to forecast revenue growth of about 24.7% per year and a longer term view of 62.1% annual growth over the next three years, which lines up with:
  • The move from US$55.3 million to US$175.1 million in trailing revenue, which helps explain why analysts frame the business as a growth story rather than a flat one.
  • The expectation that this growth will eventually support margins shifting from a current loss position toward the mid 30% range, which is a meaningful step up from the recent trailing loss of US$221.2 million.

DCF fair value US$175.0 vs US$11.20 share price

• The stock trades at a current share price of US$11.20 with a P/S of 5.1x, roughly in line with the US Pharmaceuticals industry average of 5.1x yet below a peer average of 15.8x. A DCF fair value of US$175.04 and an analyst consensus price target of US$23.70 both sit well above that market price.
• Bears highlight the combination of negative shareholders’ equity and an unprofitable trailing twelve month profile, arguing that these balance sheet and loss metrics can limit how much weight to give those higher valuation reference points, which shows up in:
  • The trailing twelve month loss of US$221.2 million and five year loss growth of about 18% per year, which are both used to justify caution even with revenue rising.
  • The gap between US$11.20, US$23.70 and a DCF fair value of US$175.04, which critics see as heavily dependent on forecasts of margin improvement and high growth actually coming through on top of a balance sheet that currently sits with negative equity.

For a closer look at why some investors lean toward the cautious side despite the large gap between market price and valuation references, you can unpack the detailed bear case in the 🐻 Phathom Pharmaceuticals Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Phathom Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

After considering both the upbeat and cautious angles in this story, it may be helpful to promptly review the underlying numbers on your own, decide where you stand, and then round out your view by checking the 2 key rewards and 1 important warning sign

See What Else Is Out There

Phathom still carries sizeable losses, negative shareholders’ equity and a valuation story that leans heavily on optimistic forecasts, which can make the risk profile feel high.

If that mix of ongoing losses and balance sheet pressure feels uncomfortable, you can quickly compare it with companies screened for stronger finances and resilience using the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com